Study summary

An anti-tau antibody was well tolerated and cut free tau in spinal fluid by about 80%

Bepranemab phase 1b · 25 people, phase 1b · Published 2026, BMJ Neurology Open

80.41%reduction in free tau in spinal fluid

What was tested

Bepranemab, an antibody that binds the middle region of the tau protein, given by infusion every 4 weeks for 52 weeks, against placebo, in PSP.

What they found

What it means

Earlier anti-tau antibodies targeting the end of the protein failed in PSP; mid-region antibodies like bepranemab are a different approach.

BMJ Neurol Open, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.